Maple Grove, Minnesota

Grove Square Galleries Hosts Another Sell-Out Exhibition

Retrieved on: 
Wednesday, August 18, 2021
Spend, Yahoo! News, Vanity Fair, Financial Times, GQ, Gallery, Wallpaper, Magic, Awareness, Time, Maple Grove, Minnesota, Exhibition, Folklore, Amusement park, Fashion

LONDON, Aug. 18, 2021 /PRNewswire/ -- Grove Square galleries are currently coming towards the end of another remarkably successful exhibition.

Key Points: 
  • LONDON, Aug. 18, 2021 /PRNewswire/ -- Grove Square galleries are currently coming towards the end of another remarkably successful exhibition.
  • Following the huge success of Orlanda Broom's 'Rewild' - which was featured in the Financial Times' 'How To Spend It' section in May Grove Square Galleries' most recent exhibition focused on the talents of Marc Standing.
  • The themes of folklore, storytelling and mystery have not only captured the magic of the continent, but also the hearts and minds of Grove Square Galleries'clientele.
  • Grove Square Galleries mentions in the press have been fairly consistent since the start of the year.

Cheryl Anderson Selected As A 2021 Women In Business Honoree By Minneapolis/St. Paul Business Journal

Retrieved on: 
Tuesday, August 3, 2021
Regions of the United States, Geography of Minnesota, Maple Grove, Minnesota, Upsher-Smith Laboratories, Geography of the United States, Minneapolis, Minnesota

MAPLE GROVE, Minn., Aug. 3, 2021 /PRNewswire/ -- Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced that Cheryl Beal Anderson, VP of Global Regulatory Affairs has been selected as a 2021 Women in Business Honoree by The Minneapolis/St.

Key Points: 
  • MAPLE GROVE, Minn., Aug. 3, 2021 /PRNewswire/ -- Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced that Cheryl Beal Anderson, VP of Global Regulatory Affairs has been selected as a 2021 Women in Business Honoree by The Minneapolis/St.
  • All of The Business Journal honorees will be featured in the October 15 Women in Business special publication, and celebrated during a Monday, October 18 event at Renaissance Minneapolis Hotel, The Depot.
  • Paul Business Journalrecognized 51 women, plus one Career Achievement honoree, for their professional achievements and contributions to the Twin Cities community.
  • Paul Business Journal is a multi-platform media company providing in-depth coverage of local business communities and breaking news reaching more than 491,000 readers each week.

Upsher-Smith And Rafarm Announce Launch Of Moxifloxacin Ophthalmic Solution, USP 0.5%

Retrieved on: 
Thursday, May 27, 2021
Chemical compounds, Drugs, Health care, Maple Grove, Minnesota, Upsher-Smith Laboratories, Moxifloxacin, Food and Drug Administration, Ophthalmic, Abbreviated New Drug Application, Anda, New Drug Application

MAPLE GROVE, Minn. and ATHENS, May 27, 2021 /PRNewswire/ -- Upsher-Smith Laboratories, LLC (Upsher-Smith) and Rafarm S.A. (Rafarm) today announced the U.S. commercial launch of Moxifloxacin Ophthalmic Solution, USP 0.5% following a recent abbreviated new drug application (ANDA)approval by the U.S. Food and Drug Administration (FDA).

Key Points: 
  • MAPLE GROVE, Minn. and ATHENS, May 27, 2021 /PRNewswire/ -- Upsher-Smith Laboratories, LLC (Upsher-Smith) and Rafarm S.A. (Rafarm) today announced the U.S. commercial launch of Moxifloxacin Ophthalmic Solution, USP 0.5% following a recent abbreviated new drug application (ANDA)approval by the U.S. Food and Drug Administration (FDA).
  • In 2018, Upsher-Smith and Rafarm entered into a partnership agreement to develop and distribute six ophthalmic and otic ANDA products.
  • "The launch of Moxifloxacin is significant because it represents a series of firsts for Upsher-Smith," said Rusty Field, President and CEO of Upsher-Smith.
  • "It is not only our first ophthalmic product to enter the market, but also the first product resulting from our partnership with Rafarm.

Upsher-Smith And The National Alliance Of State Pharmacy Associations (NASPA) Honor 42 U.S. Pharmacists For Their Excellence In Innovation

Retrieved on: 
Monday, February 8, 2021
Maple Grove, Minnesota, Upsher-Smith Laboratories, Health, Pharmacist, Pharmacy

MAPLE GROVE, Minn., Feb. 8, 2021 /PRNewswire/ -- Upsher-Smith Laboratories, LLC (Upsher-Smith) and the National Alliance of State Pharmacy Associations (NASPA) are pleased to honor the 2020 NASPA Excellence in Innovation Award recipients.

Key Points: 
  • MAPLE GROVE, Minn., Feb. 8, 2021 /PRNewswire/ -- Upsher-Smith Laboratories, LLC (Upsher-Smith) and the National Alliance of State Pharmacy Associations (NASPA) are pleased to honor the 2020 NASPA Excellence in Innovation Award recipients.
  • "Upsher-Smith is pleased to continue its long tradition of partnering with the National Alliance of State Pharmacy Associations and several state pharmacy associations to award pharmacists for their innovation, outstanding leadership and service to community," said Rusty Field, President and CEO of Upsher-Smith.
  • "For nearly a decade, The National Alliance of State Pharmacy Associations has had the opportunity to partner with Upsher-Smith to recognize pharmacists who have demonstrated an unwavering commitment to patients and dedication to advancing pharmacy," said Rebecca Snead, Executive Vice President of the National Alliance of State Pharmacy Associations.
  • We are very grateful to Upsher-Smith for supporting these pharmacists with the Excellence in Innovation Award."

Upsher-Smith Launches Ramelteon Tablets

Retrieved on: 
Tuesday, December 15, 2020
Health sciences, Health, Food and Drug Administration, Pharmaceutical industry, Maple Grove, Minnesota, Upsher-Smith Laboratories, Drug Safety, Clinical pharmacology, MedWatch, Adverse effect, Ramelteon, Medication package insert

Please refer to the full Prescribing Information for Ramelteon Tablets here .

Key Points: 
  • Please refer to the full Prescribing Information for Ramelteon Tablets here .
  • You can also call 1-888-650-3789 to obtain a copy of the full Prescribing Information.
  • You are encouraged to report suspected adverse reactions to Upsher-Smith Laboratories, LLC at 1-855-899-9180 or to the FDA by visiting http://www.fda.gov/medwatch .
  • Upsher-Smith Laboratories, LLC is a trusted U.S. pharmaceutical company that strives to improve the health and lives of patients through an unwavering commitment to high-quality products and sustainable growth.

Upsher-Smith and AmbioPharm Announce Partnership Agreement to Develop and Market Corticotropin Injection

Retrieved on: 
Friday, August 7, 2020
Hormones, Peptide hormones, Maple Grove, Minnesota, Upsher-Smith Laboratories, Adrenocorticotropic hormone, Tropic hormone, Corticotropin-releasing hormone

MAPLE GROVE, Minn. and NORTH AUGUSTA, S.C., Aug. 7, 2020 /PRNewswire/ -- Upsher-Smith Laboratories, LLC (Upsher-Smith) and AmbioPharm, Inc. (AmbioPharm) today announced that the companies have entered into a partnership agreement to develop and market Corticotropin Injection in the U.S.

Key Points: 
  • MAPLE GROVE, Minn. and NORTH AUGUSTA, S.C., Aug. 7, 2020 /PRNewswire/ -- Upsher-Smith Laboratories, LLC (Upsher-Smith) and AmbioPharm, Inc. (AmbioPharm) today announced that the companies have entered into a partnership agreement to develop and market Corticotropin Injection in the U.S.
  • The market for adrenocorticotropic hormone or ACTH (brand Acthar Gel*) is currently valued at $770 million (IQVIA, 12 months ending June 2020).
  • Under the terms of the agreement, Upsher-Smith will submit the New Drug Application for Corticotropin Injection to the U.S. Food and Drug Administration (FDA) and market and distribute it under its own label in the U.S. upon FDA approval.
  • "We are excited to partner with AmbioPharm, a leader in the field of peptide development and manufacturing, to bring Corticotropin Injection to the U.S. market," said Rusty Field, President and CEO of Upsher-Smith.

Upsher-Smith Launches Ethacrynic Acid Tablets, USP

Retrieved on: 
Tuesday, June 23, 2020
Health, Medicine, Maple Grove, Minnesota, Upsher-Smith Laboratories, MedWatch, Clinical pharmacology, Patient safety, Adverse effect, Food and Drug Administration, Pharmaceutical industry

Please refer to the full Prescribing Information for Ethacrynic Acid Tablets, USP here .

Key Points: 
  • Please refer to the full Prescribing Information for Ethacrynic Acid Tablets, USP here .
  • You can also call 1-888-650-3789 to obtain a copy of the full Prescribing Information.
  • You are encouraged to report suspected adverse reactions to Upsher-Smith Laboratories, LLC at 1-855-899-9180 or to the FDA by visiting http://www.fda.gov/medwatch .
  • Upsher-Smith Laboratories, LLC is a trusted U.S. pharmaceutical company that strives to improve the health and lives of patients through an unwavering commitment to high-quality products and sustainable growth.

Cipher Pharmaceuticals Receives Positive Ruling on Binding Arbitration with Upsher-Smith Laboratories

Retrieved on: 
Tuesday, April 21, 2020
Maple Grove, Minnesota, Upsher-Smith Laboratories, Generic drug, Articles, Life sciences, Health

OAKVILLE, ON, April 20, 2020 /CNW/ -Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced the Company has been successful in its binding arbitration with Upsher-Smith Laboratories LLC ("Upsher-Smith").

Key Points: 
  • OAKVILLE, ON, April 20, 2020 /CNW/ -Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced the Company has been successful in its binding arbitration with Upsher-Smith Laboratories LLC ("Upsher-Smith").
  • Upsher-Smith subsequently filed a second ANDA seeking approval to manufacture, use, or sell a generic version of Absorica (40 mg).
  • "Today's decision in the binding arbitration reinforces the strength of our patents and will delay Upsher-Smith's entry into the market until June 25, 2021," said Mr. Craig Mull, Interim CEO.
  • Cipher Pharmaceuticals (TSX: CPH) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products.

Upsher-Smith Launches Clonidine Hydrochloride Extended-Release Tablets

Retrieved on: 
Tuesday, January 28, 2020
Health, Medicine, RTT, Food and Drug Administration, Chloroarenes, Maple Grove, Minnesota, Upsher-Smith Laboratories, MedWatch, Pharmaceutical industry, Clonidine, Adverse effect, Medication package insert

Please refer to the full Prescribing Information for Clonidine Hydrochloride Extended-Release Tablets here .

Key Points: 
  • Please refer to the full Prescribing Information for Clonidine Hydrochloride Extended-Release Tablets here .
  • You can also call 1-888-650-3789 to obtain a copy of the full Prescribing Information.
  • You are encouraged to report suspected adverse reactions to Upsher-Smith Laboratories, LLC at 1-855-899-9180 or to the FDA by visiting http://www.fda.gov/medwatch .
  • *Kapvay is a registered trademark of Concordia Pharmaceuticals Inc.
    Do More Good is a trademark of Upsher-Smith Laboratories, LLC.

Upsher-Smith To Attend 2019 Annual Meeting Of The American Epilepsy Society

Retrieved on: 
Friday, December 6, 2019
Maple Grove, Minnesota, Upsher-Smith Laboratories, RTT, Epilepsy, Visual impairment, Economy of the United States, Health, Medicine

MAPLE GROVE, Minn., Dec. 6, 2019 /PRNewswire/ -- Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced that it will be attending the 2019 Annual Meeting of the American Epilepsy Society (AES) December 6-10, 2019 in Baltimore, MD.

Key Points: 
  • MAPLE GROVE, Minn., Dec. 6, 2019 /PRNewswire/ -- Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced that it will be attending the 2019 Annual Meeting of the American Epilepsy Society (AES) December 6-10, 2019 in Baltimore, MD.
  • All people who take VIGADRONE:
    You are at risk for permanent vision loss with any amount of VIGADRONE.
  • Your risk of vision loss may be higher the more VIGADRONE you take daily and the longer you take it.
  • It is recommended that your healthcare provider test your (or your child's) vision before, during, and after treatment with VIGADRONE.